A central role for JAK/STAT signaling in the pathogenesis of the myeloproliferative neoplasms (MPNs) was discovered by identifying the somatically acquired JAK2V617F mutation in more than 95% of patients with PV and over 50% of patients with MF and ET8. This evidence concerns the gene SOAT1 and myeloproliferative disorder.